Sino Biopharmaceutical ( (HK:1177) ) has provided an update.
Sino Biopharmaceutical Limited has received approval from the National Medical Products Administration of China to conduct a Phase I clinical trial for its self-developed drug TQB2101, intended for treating advanced malignant tumors. This approval marks a significant step in the company’s expansion of its ADC portfolio, which now includes four drugs in clinical stages. The trial will assess the safety and efficacy of TQB2101, which has shown promising preclinical results in targeting ROR1-positive tumors. This development is part of the company’s broader strategy to leverage its ADC technology platform to innovate and contribute to global health.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company in the pharmaceutical industry, focusing on the development of innovative drugs. It specializes in antibody-drug conjugates (ADCs) and has a range of products in various stages of clinical development, targeting different types of cancer.
YTD Price Performance: 16.41%
Average Trading Volume: 1,958
Technical Sentiment Signal: Sell
Current Market Cap: $9.27B
See more data about 1177 stock on TipRanks’ Stock Analysis page.